^
    Back
    Association details:
    Biomarker:FGFR1 amplification
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Truseltiq (infigratinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

    Excerpt:
    Incidence rate and category of dose-limiting toxicities will be tabulated for patients included in the dose escalation portion of the study, to establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPTD)
    Trial ID:
    NCT01004224
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

    Published date:
    11/21/2016
    Excerpt:
    Antitumor activity (seven partial responses [six confirmed]) was demonstrated with BGJ398 doses ≥ 100 mg in patients with FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancer.
    DOI:
    10.1200/JCO.2016.67.2048
    Trial ID:
    NCT01004224